Navigation Links
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting

, who are anemic due to the cancer itself. Unfortunately, the benefit of ESA treatment was not observed in these gravely ill patients," said John Glaspy, M.D., professor, David Geffen School of Medicine, University of California at Los Angeles. "Since this was not designed as a survival study and statistical significance diminished when the analyses were adjusted for known prognostic factors, there is no clear explanation for the increase of deaths in the Aranesp group."

About the Study

This Phase 3 study was designed to evaluate the efficacy and safety of Aranesp 6.75 mcg/kg administered every four weeks for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy. The study was conducted in 21 countries, including sites in Western Europe, Central and Eastern Europe, Australia and North America. The majority of patients (60 percent) were from Central and Eastern Europe.

Patient eligibility included: greater than or equal to 18 years, nonmyeloid malignancy (with active disease), hemoglobin (Hb) less than or equal to 11 g/dL, and no chemotherapy or radiotherapy treatment within four weeks of screening or during the study. Patients (n=985) were randomized to Aranesp 6.75 mcg/kg or placebo every four weeks, with an end of study visit at week 19, and two years of follow up to evaluate survival. Patients were stratified by screening Hb (less than 10 g/dL or greater than or equal to 10 g/dL), geographic region (Europe versus rest of world), RBC transfusion in the prior 12 weeks, tumor type/treatment (specifically, diagnoses of chronic lymphocyctic leukemia or low grade lymphoma, ongoing hormonal or antibody therapy versus all other eligible patients), and ECOG status (0-1, 2).

Demographics were broadly similar between the groups. The mean (SD) age was 64.1 (11.6) years; the most common cancers were non-small cell lung (18 percent), breast (13 percent), and prostate (11 percent); most patients had disease stage III o
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp ``145 Study Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Mass., March 19, 2012  Oridion (SIX Swiss Exchange: ... of the Smart Capnography™ family of decision-support solutions, ... survey conducted at the October 2011 annual meeting ... in Chicago. Respondents showed a clear preference for monitoring ...
... Fla., March 19, 2012   SurgLine International, Inc. (SGLN.PK) ... and certain consultants to SGLN and SurgLine have completed the ... Company.  This announcement is the follow up to the previous ... an additional six month lock up of the restricted shares ...
Cached Medicine Technology:Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 2Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 3Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 4SurgLine International, Inc. Announces Over 1 Billion Shares Returned to Company 2
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... 22, 2015 Lower-Auto-Insurance.com has released a new blog ... a car for reducing the costs of an auto insurance ... be able to get lower prices for their vehicle insurance policies. ... role in determining policy costs. Because of this, drivers should ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... painkillers, especially the likes of Ibuprofen and Aspirin, which come ... out or exercise. A new study has suggested that the ... work out, may ease muscle pain by 50%. ... of kinesiology at the University of Georgia, Athens, 'A lot ...
... is only too happy to perform it. ... had been diagnosed with X-linked lymphoproliferative syndrome, //a rare genetic ... affected around 100 males worldwide. ,Life expectancy ... causes the immune system to respond abnormally to some viral ...
... San Antonio, Texas has come to the rescue of a ... choice. ,This clinic aids couples who are interested ... to choose the egg //and sperm donors. The couple after ... adults decides accordingly. The complete history of the donors is ...
... books, including old and rare manuscripts on the ancient Indian ... be built at the National Ayurveda Institute at a cost ... biggest ayurveda libraries in India. It will house national and ... information under one roof. ,'The budget has already ...
... at Monash University in Australia have developed a process for ... without any moving parts, potentially allowing doctors //to do blood ... new method uses the same principle that causes tea leaves ... stirred teacup, a phenomenon first explained by Einstein in the ...
... Publishing are excited to announce the publication of the ... issue of Wound Repair and Regeneration (WRR), the premier ... continued interest by the WHS membership and with a ... developed to establish guidelines for the treatment of chronic ...
Cached Medicine News:Health News:Work-outs, Not So Much of a ‘pain’ With Caffei 2Health News:Big Brother to the Rescue 2Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... commonly prescribed for the prevention of life threatening ... However, a number of studies have shown that ... aspirin therapy to prevent a recurrent vascular event ... These people are at greater risk for a ...
... System is an embolic protection device that ... debris that may be dislodged during interventional ... components. The first is a guidewire-mounted filter, ... Other ancillary components supplied with the system ...
... is a simulator for intraocular surgery. The ... surgeon the feeling that he is experiencing ... surgeon uses instruments that feel and function ... through the EYESI microscope is similar to ...
Medicine Products: